My Treatment Approach Beyond the First-Line: Expert Insights on Evidence-Driven TKI Selection and Sequencing in Advanced GIST - Episode 5
INVICTUS Trial: Ripretinib in Fourth-Line Setting
Experts discuss the key efficacy and safety findings from the INVICTUS trial that established ripretinib in the fourth-line setting, and how the inclusion of ripretinib has influenced their approach to managing patients with heavily pretreated gastrointestinal stromal tumors (GIST).
Video content above is prompted by the following:
- The INVICTUS trial established ripretinib in the fourth-line setting. Could you review the key efficacy and safety findings from this pivotal study? Please also comment on how ripretinib changed your approach to managing patients with heavily pretreated GIST.
- So we've seen how ripretinib demonstrated significant efficacy in the fourth-line setting in INVICTUS. Building on this success, the INTRIGUE trial was designed to evaluate ripretinib earlier in the treatment sequence, specifically in the second-line setting compared to standard sunitinib. Before we discuss those data, I'd like to present a case that will help illustrate the challenges of treatment selection after first-line progression and set the stage for our discussion of the INTRIGUE results.
Related Content:
